Pharma News
US FTC clears Pfizer’s purchase of Hospira
Pharma giant Pfizer announced on 24 August 2015 that the US Federal Trade Commission (FTC) terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of US-based injectable generics specialist and biosimilars maker Hospira.
ANI Pharma and IDT Australia collaborate on US generics
US-based brand-name and generic drugmaker ANI Pharmaceuticals (ANI) announced on 12 August 2015 that it had entered into a collaboration with generics company IDT Australia (IDT) to commercialize up to 18 previously marketed US generics.
Mergers between Watson/Actavis and ANI Pharma/BioSante
Mergers are once again on the agenda as companies strive to meet the constant demands of governments to cut costs and yet still make a profit.
AstraZeneca and Fujifilm Kyowa Kirin Biologics to collaborate on bevacizumab biosimilar
Japanese biosimilars maker Fujifilm Kyowa Kirin Biologics announced on 24 July 2015 that it had entered into an agreement with pharma giant AstraZeneca to establish a joint venture for the development and commercialization of its candidate biosimilar, FKB238.
Hikma to acquire Boehringer Ingelheim’s US generics business
Jordan-based drugmaker Hikma Pharmaceuticals (Hikma) announced on 28 July 2015 that it had made a deal with Germany’s Boehringer Ingelheim to acquire the latter’s US generics business: Roxane Laboratories and Boehringer Ingelheim Roxane (Roxane).
Lupin to expand US generics business with Gavis acquisition
Indian generics manufacturer Lupin Pharmaceuticals (Lupin) announced on 23 July 2015 that it had entered into a definitive agreement to acquire US generics makers Gavis Pharmaceuticals and Novel Laboratories (Gavis).
Acquisitions for Endo and Strides
Endo Pharmaceuticals (Endo) and Strides Arcolab (Strides) are both looking at acquisitions as a way to expand their generics businesses.
Amneal to acquire Australian generics business from Actavis
Privately held US generics maker Amneal Pharmaceuticals (Amneal) announced on 31 March 2015 that it had made a deal with the Australian subsidiary of Actavis to acquire the Australian generics business of Actavis for an undisclosed amount.
Anticompetitive acquisition forces generics sale
US generics maker CorePharma has had to sell its rights of two generics in order to merge with fellow US drug company Impax Laboratories (Impax). The US Federal Trade Commission (FTC) ruled that Impax’s acquisition of CorePharma would have been anticompetitive unless CorePharma sold its rights and assets for pilocarpine, a drug used to treat dry mouth and glaucoma, and ursodiol, a treatment for liver and gall bladder diseases.
Teva finally makes bid for Mylan
In the wake of many rumours, Israeli generics giant Teva Pharmaceutical Industries (Teva) finally announced on 21 April 2015 that it had made a bid for US-based generics maker Mylan.
